Introduction
============

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal (GI) diseases with the prevalence of around 20% in the general population [@B1]-[@B3]. The Rome diagnostic criteria are the diagnostic standard for research and clinical care of IBS [@B4], [@B5]. According to the predominant stool pattern, IBS is traditionally classified into four subtypes; IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed IBS (IBS-M) and non-subtyped IBS (IBS-U) [@B6]. Typical symptoms of IBS include recurrent abdominal pain, bloating, change in bowel habits without detectable structural or biochemical abnormalities [@B7]. IBS is associated with poor quality of life, impaired social functions [@B8], [@B9] and psychological-psychiatric conditions, such as depression [@B10]; approximately 20-40% of IBS patients present with depressive symptoms [@B11], [@B12].

The close association between IBS and depression is supported by psychophysiological and neuro-imaging studies [@B13], [@B14], and this association might be related to the \'brain-gut axis\' that is defined as the bidirectional connecting system through neural, neuroimmune and neuroendocrine pathways between the digestive system and the brain [@B15]. Psychosocial factors can affect the gut physiology via the brain-gut axis in IBS [@B10], [@B16]. Antidepressants are effective to some extent in treating IBS directly through the brain-gut axis independent of changes in depressive symptoms [@B17], [@B18].

The relationship between IBS and depression has not been consistent across studies. IBS has been associated with more severe depressive symptoms compared to healthy controls in some [@B19]-[@B22], but not all [@B23], [@B24] studies. Additionally, the association between IBS subtype and depressive symptoms is also uncertain with studies finding either an association with IBS-C [@B25] or IBS-D [@B26], [@B27] but not with other subtypes [@B25], or not at all[@B28], [@B29].

Two meta-analyses [@B27], [@B30] concluded that IBS patients had more severe depressive symptoms than healthy controls, but the association between IBS subtypes and depressive symptoms was inconsistent. These studies only covered English databases and the included studies employed self-reported scales on depressive symptoms, such as the Hospitalization Anxiety and Depression Scale (HADS) and the Beck Depression Inventory (BDI). As the reliability of self-reported scales are affected by impaired insight and cognitive functions that are common in depression, investigator-rated tools, such as the Hamilton Depression Rating Scale (HAMD) [@B31], [@B32] are generally thought to be more objective and suitable for research purposes.

To the best of our knowledge, no meta-analysis or systemic review on depressive symptoms in IBS using interviewer-rated tools have been published. Thus, the aim of this study was to conduct a systematic meta-analysis to compare objectively rated depressive symptoms between IBS patients and healthy controls, and examine the association between IBS subtypes and depressive symptoms.

Methods
=======

Search strategy
---------------

The meta-analysis was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [@B33]. Two authors (ZQE and WF) independently performed a literature search using both English (PubMed, PsycINFO, Embase, Cochrane Library) and Chinese (Wan Fang, SinoMed and Chinese National Knowledge Infrastructure (CNKI)) databases, from their inception to September 12, 2017 with the following search terms: (\"irritable bowel syndrome\" OR \"colon diseases, functional\" OR \"functional bowel diseases\" OR \"IBS\") AND (\"depressive\" OR \"depression\" OR \"melancholia\"). Furthermore, the references of included studies, meta-analyses and review papers were manually searched [@B27], [@B30], [@B34] to identify additional relevant studies.

Selection criteria
------------------

The search results were imported into the EndNote X7 software (Thomson Reuters, Philadelphia, PA, USA). The inclusion criteria were based on the *PICOS* acronym: Participants (*P*): Patients with IBS according to any diagnostic criteria. Intervention (I): not applicable. Comparison (C): healthy controls. Outcomes (O): depressive symptoms assessed with validated interviewer-rated scales. To assess depressive symptoms more objectively, only studies using investigator-rated scales were included. Study design (*S*): published case-control, cohort (only baseline data were included) and cross-sectional studies. Studies were excluded if they (1) made no comparisons between patients with IBS/IBS subtype and healthy controls; (2) did not provide meta-analyzable data on depressive symptoms. If more than one publication were published based on the same dataset, only publications with complete data were included.

Data extraction
---------------

Two reviewers (ZQE and WF) independently checked and extracted data from the studies using a pre-defined electronic Excel form: first author, year of publication, country, study design, IBS diagnostic criteria, and the assessment tools and means and standard deviations (SDs) of depressive symptoms. The first or corresponding authors were contacted for more information if relevant data were incomplete. Extracted data were analyzed independently by two reviewers (ZQE and QG). Any controversy was resolved by consensus or with the involvement of a third reviewer (WZ).

Statistical analysis
--------------------

Data analyses were performed using the Review Manager Version 5.3 software (<http://www.cochrane.org>) and the Comprehensive Meta Analysis, Version 2.2.064 (<http://www.Meta-Analysis.com>), according to the recommendation of the Cochrane Handbook for Systematic Reviews [@B35]. Due to the unavoidable heterogeneity in study characteristics, the random effects model was used to synthesize the data. Heterogeneity was examined by the I^2^ and Q statistics. Significant heterogeneity was considered when I^2^ values were of \>50% or P\<0.1 in the Q statistics [@B36], [@B37]. For continuous and dichotomous outcomes SMDs and odds ratios (OR), respectively were calculated to evaluate the results\' effect size (ES). ES values over 0.8, 0.5-0.8 and 0.2-0.5 constituted large, medium and small effect sizes, respectively [@B38]. Subgroup and sensitivity analyses were conducted to explore potential sources of heterogeneity. Subgroup analyses were performed according to the following variables: 1) subtypes: IBS-C vs. IBS-D vs. IBS-M vs. IBS-U; 2) Chinese studies vs. non-Chinese studies; 3) IBS diagnostic criteria: Rome I *vs*. Rome II *vs*. Rome III; 4) treatment settings: inpatients *vs*. outpatients vs. mixed; 5) HAMD versions: HAMD-17 *vs*. HAMD-24 vs. HAMD-not reported (NR); 6) refractory *vs*. non-refractory IBS. Random effects meta-regression was used to evaluate the impact of continuous moderating variables, such as age, proportion of females, sample size and the Newcastle-Ottawa Scale (NOS) scores with the primary outcome [@B39]. Potential publication bias was assessed with the funnel plots and Egger\'s regression test [@B40], [@B41].

Assessment of study quality
---------------------------

Two reviewers (ZQE and WF) independently evaluated the methodological quality of each study using the NOS [@B42], [@B43], which has a score ranging from 0 to 9 points. The total NOS score of ≥7 points were rated as high quality [@B44], [@B45].

Results
=======

Literature search
-----------------

Out of 6,654 studies, 4,071 were identified after duplicate publications were removed. Eventually, 24 studies met full criteria and were included in the meta-analysis. The screening process according to the PRISMA flow diagram is presented in Figure [1](#F1){ref-type="fig"}. One study [@B46] reported data on both refractory and non-refractory IBS patients separately, therefore the data were extracted and analyzed as two separate arms. In order to avoid inflating the sample size in the control group, half numbers of healthy controls were assigned to each arm in the analyses.

Study characteristics
---------------------

There were 2,837 subjects (1,775 IBS patients and 1,062 healthy controls) in the 24 studies (Table [1](#T1){ref-type="table"}). Twenty studies were conducted in China (n=2,620) [@B46]-[@B65], and one each in Serbia (n=60) [@B66], The Netherlands (n=46) [@B67], United Kingdom (n=29) [@B68] and Turkey (n=76) [@B69]. IBS was diagnosed using the Rome I criteria in one [@B69], Rome II criteria in 10 [@B50], [@B56], [@B58]-[@B60], [@B62], [@B65]-[@B68], and Rome III criteria in 13 studies [@B46]-[@B49], [@B51]-[@B55], [@B57], [@B61], [@B63], [@B64]. The severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale (HAMD-17) in 5 studies [@B46], [@B61], [@B65], [@B67], [@B69] and HAMD-24 in 9 studies [@B50]-[@B53], [@B55], [@B57], [@B60], [@B63], [@B64], but HAMD versions that were not reported (HAMD-NR) in 10 studies [@B47]-[@B49], [@B54], [@B56], [@B58], [@B59], [@B62], [@B66], [@B68]. One study included female subjects only [@B56]. The mean age ranged from 32.9 to 63.7 years, and the proportion of males ranged from 0% to 69.6% in the patient group.

Quality assessment
------------------

The NOS score assessing quality of the studies ranged from 4 to 8 points (Supplemental Table [1](#SM0){ref-type="supplementary-material"}); 58.3% of studies (n=14) [@B46], [@B48]-[@B50], [@B52]-[@B55], [@B57], [@B63], [@B64], [@B66], [@B67], [@B69] were assessed as "high quality" (NOS≥7).

Primary outcome
---------------

Compared to healthy controls, IBS patients had more severe depressive symptoms (n=1,480, SMD=2.02, 95%CI: 1.56-2.48, P\<0.001; Figure [2](#F2){ref-type="fig"}). The funnel plot showed asymmetry, while Egger\'s regression test showed publication bias (P=0.005). Sensitivity analysis revealed that the significance in bias remained (n=1,334, SMD=1.51, 95%CI: 1.16-1.86, P\<0.001) after excluding three outlying studies (i.e., SMD\>3) [@B59], [@B62], [@B65]. Subgroup analyses further revealed that the significance remained in all of the 18 subgroup analyses (Table [2](#T2){ref-type="table"}; Supplemental figure [3](#SM0){ref-type="supplementary-material"}). In addition, IBS diagnostic criteria (p=0.01) and HAMD versions (p=0.002) were significantly associated with more severe depressive symptoms compared with the control group (Table [2](#T2){ref-type="table"}). In meta-regression analyses younger age (slope=-0.033, p\<0.001), proportion of female gender (slope=0.021, p\<0.001) and small sample size (slope=-0.002, p\<0.001) were significantly associated with more severe depressive symptoms. NOS scores did not have significant impact on the primary outcome (slope =0.095, P=0.08).

Secondary outcomes
------------------

The Hamilton Depression Rating Scale (HAM-D) contains six separate factors, namely factor I (anxiety/somatization), factor II (weight), factor III (cognitive disturbance), factor IV (diurnal variation), factor V (psychomotor retardation) and factor VI (sleep disturbances) [@B70]-[@B73]. Compared to healthy controls, IBS patients had significantly higher scores in most HAM-D factors (SMD=4.03 to 13.54, 95%CI: 1.28-22.45, P\<0.001; I^2^=41% to 99%, Supplemental Figure [2](#SM0){ref-type="supplementary-material"}): anxiety/somatization (SMD=4.03), weight (SMD=4.78), psychomotor retardation (SMD=4.23) and sleep disturbances (SMD=13.54).

Prevalence of depressive symptoms (HAM-D total score \> 7) in IBS patients was higher than in healthy controls (OR=9.21, 95%CI: 4.56-18.57, P\<0.001; I^2^=76%, Figure [3](#F3){ref-type="fig"}). In addition, there was higher prevalence of mild depressive symptoms (HAM-D total score: 8-19) (OR=2.69, 95%CI: 1.21-5.95, P=0.01; I^2^=74%, Figure [3](#F3){ref-type="fig"}) as well as moderate to severe depressive symptoms (HAM-D total score ≥ 20) (OR=10.45, 95%CI: 4.45-24.50, P\<0.001; I^2^=0%, Figure [3](#F3){ref-type="fig"}) in the IBS group than in the control group.

Discussion
==========

This was the first meta-analysis on the frequency and severity of depressive symptoms measured by rater-administered scales in IBS. In psychiatric research the HAM-D is the most widely used scale of depressive symptoms with good psychometric properties [@B74], [@B75]. All studies in this meta-analysis measure the presence and severity of depressive symptoms using HAM-D scales, which significantly decreases the heterogeneity attributed to different assessment instruments.

In this study, compared to healthy controls IBS patients had more severe depressive symptoms overall (SMD=2.02) and also in specific domains, namely anxiety/somatization (SMD=4.03), weight (SMD=4.78), psychomotor retardation (SMD=4.23) and sleep disturbances (SMD=13.54). Further, depressive symptoms were more frequent in IBS patients (OR=9.21), particularly moderate to severe depressive symptoms (OR=10.45). Both frequency and severity of depressive symptoms were higher in this study than in other meta-analyses [@B27], [@B30], which may be due to several reasons. First, this study focused more broadly on depressive symptoms rather than major depressive disorder. Second, studies of this meta-analysis only used the HAMD scales, which maintained the homogeneity of assessment compared to other meta-analyses that covered studies employing different self-reported tools to evaluate depressive symptoms [@B27], [@B30]. It is likely that patients who had severe to very severe depressive symptoms were unable to complete self-reported scales and were therefore excluded from studies included in previous meta-analyses. Using rater-administered scales is more likely to include patients with wider range of severity which could lead to a larger effect size in this study.

In this study all IBS subtypes were associated with increased risk of the development of depressive symptoms. Patients with IBS-M showed the largest effect size (SMD = 2.50; 95% CI, 1.86-3.14), which is different from studies that found IBS-C/IBS-D with the largest effect size [@B18], [@B25], [@B26]. Possible factors for this discrepancy may relate to the different number of included studies and measures of depressive symptoms across meta-analyses.

Subgroup and meta-regression analyses found that HAM-D versions (HAMD-17, HAMD-24 and HAMD-NR), IBS diagnostic criteria (ROME I, ROME II and ROME III), younger age, female gender and small sample size were significantly associated with more severe depressive symptoms. In terms of gender differences, earlier studies [@B76] found that women with IBS had more severe IBS symptoms and lower quality of life than men, regardless of diagnostic criteria used. In addition, the prevalence of IBS in women is approximately 1.5 to 3 fold higher than in men [@B77]-[@B80]. Further, in IBS patients with severe symptoms (\>3 Manning criteria), 80% are women. The consensus in the literature is that women have more anxiety and depressive symptoms than men with IBS [@B81], which is supported by the current study, but not others [@B30].

IBS occurs in all age groups [@B82] although around half of those with IBS develop initial symptoms before age of 35 years [@B83]. As the prevalence of IBS and severity of pain usually decrease after the age of 50 years [@B84], there may be less depressive symptoms in older patients, which is consistent with our findings. Different sample sizes could influence the power to detect significant results [@B38], which could account for the association between sample size and the prevalence of depressive symptoms. The findings of clinical trials with small sample size are usually not stable, thus results of small studies should be interpreted with caution [@B85].

A previous study [@B30] showed no significant association between IBS diagnostic criteria and severity of depressive symptoms. However, in this study patients diagnosed according to Rome II or Rome III criteria had more severe depressive symptoms than healthy controls, while no significant difference was found between those diagnosed with Rome I criteria and controls. Reasons for the discrepancy may include the different depression scales used (self-reported scales vs. interviewer-rated scales) and the differences between the three diagnostic criteria in terms of the frequency and severity of IBS symptoms. For example, more IBS symptoms and stringent severity were adopted in Rome II than Rome III criteria, while Rome III criteria contain more items on the socioeconomic burden of IBS than Rome II [@B86]. Further, only one study using Rome I was included in this meta-analysis.

The results of this meta-analysis should be interpreted with caution due to several methodological limitations. First, studies included in the meta-analysis focused on depressive symptoms, but not major depressive disorder. The prevalence studies of major depressive disorder in IBS needs more sophisticated methodology. Second, there was publication bias in the meta-analysis. Third, high heterogeneity remained in some subgroup analyses. Fourth, relevant variables related to IBS, such as pharmacotherapy, were not examined due to incomplete information. Finally, most studies were conducted in China, which may lead to selection bias.

In conclusion, patients with IBS of all subtypes had more frequent and severe depressive symptoms than healthy controls, particularly female and younger patients. Regular screening on depressive symptoms and effective interventions should be developed for this patient population.
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###### 

Characteristics of the studies included in the meta-analysis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                             Country          N     Design, n\                 Assessment scales on depressive symptoms   Patients with IBS   Healthy controls   NOS\                                                                                
                                                             (IBS/control)                                                                                                scores                                                                              
  ----------------------------------- ---------------- ----- -------------------------- ------------------------------------------ ------------------- ------------------ -------- ------ ---------------------------------------------------- ------- ------ ---
  Akkus et al, 2004                   Turkey           82    Case control,\             HAMD-17                                    Rome I              Outpatients        44.8     59.4   Hospital staff;\                                     47.6    44.0   7
                                                             32/50                                                                                                                        Healthy volunteers                                                  

  Chen and Wang et al, 2007           China            60    Case control,\             HAMD                                       Rome II             Inpatients;\       NR       40.0   Health examination population; Healthy volunteers    NR      43.3   8
                                                             30/30                                                                                     Outpatients                                                                                            

  Chen and Zou et al, 2007            China            54    Case control,\             HAMD-24                                    Rome II             Outpatients        40.3     44.4   Health examination population                        37      48.2   6
                                                             27/27                                                                                                                                                                                            

  Gonçalves de Medeiros et al, 2012   United Kingdom   27    RCT,\                      HAMD                                       Rome II             Outpatients        39.9     23.8   Healthy volunteers                                   32.3    75.0   6
                                                             21/8                                                                                                                                                                                             

  Hao et al, 2015                     China            50    Case control,\             HAMD                                       Rome III            Inpatients         38^C^    53.3   Health examination population                        42^C^   55.0   8
                                                             30/20                                                                                                                                                                                            

  Jin et al, 2004                     China            58    RCT,\                      HAMD-17                                    Rome II             Inpatients;\       42.7     44.4   Health examination population                        41.1    59.1   5
                                                             36/22                                                                                     Outpatients                                                                                            

  Kilkens et al, 2013                 Netherlands      46    Case control, 23/23        HAMD-17                                    Rome II             Outpatients        32.9     39.1   Healthy volunteers                                   28.6    39.1   8

  Li and Chen et al, 2015             China            140   Case control, 70/70        HAMD-24                                    Rome III            Outpatients        51.0     48.6   Health examination population                        49      50.0   7

  Li et al, 2015                      China            64    Case control, 32/32        HAMD-24                                    Rome III            Inpatients;\       40.8     34.4   Health examination population; Healthy volunteers    39      31.3   8
                                                                                                                                                       Outpatients                                                                                            

  Liu et al, 2013                     China            801   Cross-sectional, 601/100   HAMD-17                                    Rome III            Outpatient         38.3     49.5   Health examination population                        39.7    45.0   7

  Mao et al, 2010                     China            96    Case control, 56/40        HAMD                                       Rome III            Inpatients         35.2     32.1   Health examination population                        32.2    35.0   6

  Mu et al, 2003                      China            60    Case control, 30/30        HAMD                                       Rome II             Outpatients        NR       33.3   Hospital staff                                       NR      40.0   5

  Shi et al, 2012                     China            90    Case control,\             HAMD-24                                    Rome III            Inpatients;\       NR       30.0   Health examination population                        NR      66.7   8
                                                             60/30                                                                                     Outpatients                                                                                            

  Shi and Zhang et al, 2012           China            57    Case control, 32/25        HAMD-17                                    Rome III            Outpatients        40.0     40.6   NR                                                   39.2    56.0   6

  Song et al, 2015                    China            204   Case control, 102/102      HAMD-24                                    Rome III            Outpatients        48.1     38.2   Health examination population                        42.3    42.2   7

  Tian et al, 2011                    China            30    Case control, 20/10        HAMD                                       Rome III            NR                 45^C^    55.0   Health examination population                        42^C^   60.0   7

  Tosic-Golubovic et al, 2010         Serbia           60    Case control, 30/30        HAMD                                       Rome II             Outpatients        43.9     50.0   Community                                            41.6    50.0   8

  Wan et al, 2005                     China            50    Case control, 30/20        HAMD                                       Rome II             Outpatients        37.0     0      Hospital staff; Patient\'s relative; Students        38      0      6

  Wang et al, 2012                    China            116   Case control, 56/60        HAMD-24                                    Rome II             Inpatients;\       NR       NR     Health examination population; Patient\'s relative   NR      NR     6
                                                                                                                                                       Outpatients                                                                                            

  Wang et al, 2014                    China            260   Case control, 150/110      HAMD                                       Rome III            NR                 NR       41.3   Health examination population; Patient\'s relative   NR      NR     8

  Xu et al, 2012                      China            134   Case control, 69/65        HAMD-24                                    Rome III            Inpatients;\       NR       42.0   Hospital staff; Patient\'s relative                  NR      50.8   8
                                                                                                                                                       Outpatients                                                                                            

  Xu et al, 2014                      China            215   Case control, 112/103      HAMD-24                                    Rome III            Outpatients        63.7     69.6   Healthy volunteers                                   56.3    57.3   5

  Xu et al, 2017                      China            66    Cross-sectional, 46/20     HAMD-24                                    Rome III            Outpatients        34.2     49.1   Healthy volunteers                                   29.5    60.0   8

  Zhang et al, 2007                   China            115   Case control, 80/35        HAMD                                       Rome II             NR                 20-73    55.0   NR                                                   20-60   45.7   5
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Only data from IBS subjects and healthy control groups were extracted if there were multiple study arms.

^b^ Rome I/II/III are standard criteria for diagnosis of IBS.

^c^ median age.

HAMD=Hamilton Depression Rating Scale; IBS= irritable bowel syndrome; NR=not reported; NOS=Newcastle-Ottawa Scale; yrs=years; RCT=randomized controlled trial.

###### 

Subgroup analyses of moderating variables of the primary outcome

  subgroups                Study arms (subjects)   SMDs (95%CI)        *I^2^* (%)   P~h~^a^       P-value for each subgroup   P-value across subgroups
  ------------------------ ----------------------- ------------------- ------------ ------------- --------------------------- --------------------------
  Overall                  18 (1480)               2.02 (1.56, 2.48)   94           **\<0.001**   **\<0.001**                 NA
  Subtypes                                                                                                                    
  IBS-C                    6 (145)                 2.38 (1.10, 3.67)   95           **\<0.001**   **0.0003**                  0.81
  IBS-D                    7(253)                  2.08 (1.46, 2.70)   86           **\<0.001**   **\<0.001**                 
  IBS-M                    3(27)                   2.50 (1.86, 3.14)   26           0.26          **\<0.001**                 
  IBS-U                    2(33)                   2.21 (1.69, 2.72)   0            0.66          **\<0.001**                 
  Study setting                                                                                                               0.12
  China                    14 (1374)               2.17 (1.62, 2.71)   95           **\<0.001**   **\<0.001**                 
  Other countries^b^       4 (106)                 1.50 (0.86, 2.15)   74           **0.008**     **\<0.001**                 
  IBS diagnosis criteria                                                                                                      **0.01**
  Rome I                   1 (32)                  1.39 (0.90, 1.88)   NA           NA            **\<0.001**                 
  Rome II                  9 (307)                 2.95 (1.95, 3.95)   93           **\<0.001**   **\<0.001**                 
  Rome III                 8 (1141)                1.30 (0.85, 1.74)   92           **\<0.001**   **\<0.001**                 
  Patients                                                                                                                    0.15
  Inpatients               2 (86)                  1.42 (1.05, 1.79)   0            0.62          **\<0.001**                 
  Outpatients              11 (1078)               1.57 (1.14, 1.99)   91           **\<0.001**   **\<0.001**                 
  Mixed                    2 (66)                  4.39 (0.94, 7.84)   95           **\<0.001**   **0.01**                    
  NR                       3 (250)                 2.85 (1.16, 4.54)   95           **\<0.001**   **0.0009**                  
  HAM-D version                                                                                                               **0.002**
  HAMD-17                  4 (692)                 2.06 (1.19, 2.94)   94           **\<0.001**   **\<0.001**                 
  HAMD-24                  4 (311)                 1.00 (0.51, 1.49)   87           **\<0.001**   **\<0.001**                 
  NR                       10 (477)                2.42 (1.74, 3.10)   92           **\<0.001**   **\<0.001**                 
  IBS severity                                                                                                                0.11
  Refractory IBS           3 (208)                 3.43 (1.50, 5.36)   96           **\<0.001**   **0.0005**                  
  Non-refractory IBS       16 (1272)               1.80 (1.32, 2.27)   94           **\<0.001**   **\<0.001**                 

^a^ P-value of heterogeneity analysis.

^b^ One study each in Turkey, Serbia, Netherlands, and in the United Kingdom.

NA=Not applicable; NR=Not reported; SMDs=Standard mean differences; IBS-C=Constipation-predominant Irritable Bowel Syndrome; IBS-D=Diarrhea-predominant irritable bowel syndrome; IBS-M=Mixed Irritable Bowel Syndrome; IBS-U=Un-subtyped Irritable Bowel Syndrome; Rome I/II/III=A standardize criteria for diagnosis of IBS; HAM-D=Hamilton Depression Rating Scale.
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